The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial

Geahča maid

• Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
  Dahkki: Borthwick, N, et al.
  Almmustuhtton: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
  Dahkki: Ondondo, B, et al.
  Almmustuhtton: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
  Dahkki: Ondondo, B, et al.
  Almmustuhtton: (2013)
• Targeting HIV-1 Where It Hurts
  Dahkki: Ahmed, T, et al.
  Almmustuhtton: (2013)
• Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
  Dahkki: Hancock, G, et al.
  Almmustuhtton: (2017)